Reversing chemoresistance in ovarian cancer: network pharmacology reveals how hydroxychloroquine/sulfasalazine duotherapy remodels tumor inflammatory-immune microenvironment.

Authors

Xin Hong, Xin Wen, Ting Zhang, Yihao Liu, Yu Ji, Xiaoyan Shen

Published in

Frontiers in immunology. Volume 17. Pages 1790210. Epub Mar 26, 2026.

Abstract

Chemoresistance is a key contributor of ovarian cancer (OC) mortality. Clinical observations of extended survival in OC patients with rheumatic comorbidities following anti-rheumatic treatment suggest hydroxychloroquine (HCQ) and sulfasalazine (SSZ) could act as chemosensitizers. However, how the HCQ/SSZ combination counteracts platinum-taxane resistance remains unclear.
A multiomics strategy was applied, integrating transcriptomics from resistant and sensitive OC models with network pharmacology, consensus clustering, machine learning, and molecular docking, which indicated potential binding to predicted targets (e.g., SSZ-tumor necrosis factor (TNF): -6.99 kcal/mol). Validation included in vitro drug sensitivity assays and clinical cytokine profiling.
Analysis identified 26 overlapping genes as shared targets and classified patients into chemoresistant (Subtype 1) and chemosensitive (Subtype 2) subgroups, with Subtype 1 associated with protumorigenic pathway enrichment, immunosuppressive features, and poorer prognosis. A seven-hub-gene predictive signature was established. HCQ/SSZ appeared to remodel the inflammatory-immune tumor microenvironment, primarily through cytokine and nuclear factor kappa B (NF-κB) signaling. Clinical cytokine data supported a localized immunosuppressive niche, and in vitro evidence confirmed cytotoxic effects. Patients receiving long-term HCQ/SSZ therapy generally showed improved clinical outcomes.
This study suggests that HCQ/SSZ may reverse chemoresistance by reprogramming the inflammatory-immune microenvironment, offering a molecular rationale for further investigation into their repurposing as chemosensitizers and maintenance therapies in OC.

PMID:
41972182
Bibliographic data and abstract were imported from PubMed on 20 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.